Biolife solutions stock.

Stock Information. The interactive chart below shows a historical timeline of our stock price and trading volume. Click on the tabs below to view the different timeframes. You may also view data on Dividend, Split, and Earning History by using the Events tab. NASDAQBLFS. 5d. 1m. 3m. 6m.According to the issued ratings of 5 analysts in the last year, the consensus rating for BioLife Solutions stock is Buy based on the current 5 buy ratings for BLFS. The average twelve-month price prediction for BioLife Solutions is $24.60 with a high price target of $28.00 and a low price target of $22.00. Learn more on BLFS's analyst rating ...In today’s fast-paced world, personal health tracking has become increasingly important. With the rise of digital technology, there are now numerous apps available to help individuals monitor and improve their well-being.Aug 9, 2022 · BOTHELL, Wash., Aug. 9, 2022 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapies ("CGT") and the broader biopharma markets, today announced financial results for the three and six months ended ... –BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.

BioLife Solutions, Inc. (BLFS) delivered earnings and revenue surprises of -27.78% and 10.07%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

BioLife Solutions, Inc. : News, information and stories for BioLife Solutions, Inc. | Other OTC: | Other OTCBioLife Solutions, Inc. (NASDAQ: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced ...

Dec 4, 2023 · Rhumbline Advisers decreased its holdings in BioLife Solutions, Inc. (NASDAQ:BLFS – Free Report) by 8.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 80,251 shares of the medical equipment provider’s stock after selling 7,097 shares during the period. Rhumbline Advisers’ holdings in BioLife Solutions were worth $1,774,000 as of its most recent […] First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...16 mar 2023 ... Share this article · Cell Processing platform revenue was $68.5 million, up $23.5 million, or 52%, over 2021. · Freezers and Thaw Systems platform ...BioLife Solutions Trading Up 2.5 %. NASDAQ BLFS traded up $0.33 on Monday, hitting $13.58. 44,504 shares of the stock were exchanged, compared to its average volume of 403,529. The company’s 50 ...

BioLife Solutions, Inc. (NASDAQ:BLFS) Q3 2023 Earnings Call Transcript November 9, 2023 BioLife Solutions, Inc. beats earnings expectations. Reported EPS is $-0.3, expectations were $-0.38. Operator: Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions Third Quarter 2023 Shareholder and Analyst ...

Get the latest BioLife Solutions, Inc. (BLFS) stock news and headlines to help you in your trading and investing decisions.

Todd Berard, BioLife's Chief Marketing Officer, commented, "With a capacity that's 40% larger than other tabletop CRFs, IntelliRate i67C is perfectly sized to efficiently scale precision rate freezing as a customer's capacity needs grow. We designed the IntelliRate i67C to increase single-batch, LN2 CRF capacity from mid- and late-stage …May 19, 2023 · Shareholder Director Nominations. The Board of Directors of BioLife Solutions, Inc., a Delaware corporation, (the " Company ") determined that the Company's 2023 Annual Meeting of Stockholders (the " Annual Meeting ") will be held on July 21, 2023. It is expected that the Annual Meeting will be held virtually on the internet, but the time and ... Buy BioLife Solutions Stock. BioLife Solutions is a medical instruments & supplies business based in the US. BioLife Solutions shares (BLFS.US) are listed on the NASDAQ and all prices are listed in US dollars. Its last market close was $13.54 – an increase of 2.11% over the previous day.On average, Wall Street analysts predict. that Biolife Solutions's share price could reach $25.50 by Aug 10, 2024. The average Biolife Solutions stock price prediction forecasts a potential upside of 103.84% from the current BLFS share price of $12.51.–BioLife Solutions, Inc. (Nasdaq: BLFS) (“BioLife” or the “Company”), a leading developer and supplier of class-defining bioproduction products and services for the cell and gene therapy (CGT) and the broader biopharma markets, today announced financial results for the fourth quarter and year ended December 31, 2022.BioLife Solutions is expected to report its next quarterly earnings on March 12, 2020. TrendSpider From a technical standpoint, the stock opened higher and closed sharply lower during Thursday's ...

Chg %. Market Cap. Evogene Ltd. -0.32%. $32.76M. BLFS | Complete BioLife Solutions Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …May 19, 2023 · Shareholder Director Nominations. The Board of Directors of BioLife Solutions, Inc., a Delaware corporation, (the " Company ") determined that the Company's 2023 Annual Meeting of Stockholders (the " Annual Meeting ") will be held on July 21, 2023. It is expected that the Annual Meeting will be held virtually on the internet, but the time and ... Supplier: BIOLIFE SOLUTIONS INC 210373. This item has a minimum qty of 4 per supplier requirements. The CryoStor series of cell-specific, optimized freeze media, is designed to prepare and preserve cells in ultra low temperature environments (-70C to -196C). CryoStor CS10, pre-formulated with 10% DMSO, provides a safe, protective environment ...Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Solutions, Inc. Common Stock (BLFS) Stock Price, Quote, News & History | Nasdaq. Nasdaq Data Link's products page. Investors may trade in the Pre-Market (4:00 …

Maximize post-thaw cell recovery and viability following cryopreservation at low temperatures (-80°C to -196°C) with ready-to-use CryoStor® CS5. Serum-free, animal component-free, and cGMP-manufactured, this defined medium provides a safe, protective environment for cells and tissues during freezing and thawing processes and storage.

Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors BioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Our tools portfolio includes our proprietary CryoStor® freeze media and ...BioLife Solutions, Inc. is a life sciences company. The Company develops, manufactures, and markets bioproduction tools and services which are designed to de-risk biologic manufacturing, storage, distribution, and transportation in the cell and gene therapy (CGT) industry and broader biopharma markets.Biolife Solutions Inc (NASDAQ:BLFS) has a beta value of 1.60 and has seen 2.24 million shares traded in the last trading session. The company, currently valued at $596.91M, closed the last trade at $13.25 per share which meant it gained $0.88 on the day or 7.11% during that session. The BLFS stock ...BOTHELL, Wash., July 2, 2020 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of class-defining bioproduction tools for cell and gene therapies, today announced the pricing of its public offering of 5,175,000 shares of its common stock at a public offering price of $14.50 per share, before underwriting ...Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] Supplier: BIOLIFE SOLUTIONS INC 210373. This item has a minimum qty of 4 per supplier requirements. The CryoStor series of cell-specific, optimized freeze media, is designed to prepare and preserve cells in ultra low temperature environments (-70C to -196C). CryoStor CS10, pre-formulated with 10% DMSO, provides a safe, protective environment ...Under the terms of the agreement, BioLife will pay $15 million in cash and $15 million in newly issued shares of BioLife common stock for 100% of the outstanding shares of SciSafe. ... About BioLife Solutions BioLife Solutions is a leading supplier of a portfolio of class-defining cell and gene therapy bioproduction tools and services.

BOTHELL, Wash., Nov. 4, 2021 / PRNewswire / -- BioLife Solutions, Inc. (the "Company") (Nasdaq: BLFS), a leading supplier of class-defining bioproduction tools and services for the cell and gene therapies ("CGT") and broader biopharma markets, today announced changes to its executive management team, effective immediately.

msn.com - November 17 at 10:30 PM. BioLife Solutions (BLFS) was Impacted by Inventory Destocking and Elongated Sales Cycles. finance.yahoo.com - November 16 at 10:07 AM. Analysts Just Shaved Their BioLife Solutions, Inc. (NASDAQ:BLFS) Forecasts Dramatically. finance.yahoo.com - November 16 at 10:07 AM.

BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC. Oct. 18. CI. Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating. Aug. 09. MT. Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023. Aug. 08.Jan 5, 2023 · First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ... While BioLife Solutions, Inc. ( NASDAQ:BLFS) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the NASDAQCM, rising to highs ...Broadridge Corporate Issuer Solutions, Inc. P.O. Box 1342 Brentwood, New York 11717 USA (877) 830 - 4936 [email protected] you’re looking to donate plasma, Biolife Plasma Centers are a fantastic option. They offer convenient locations, a streamlined donation process, and compensation for your time. In this comprehensive guide, we’ll cover everything you need...On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...The estimated net worth of Sarah Aebersold is at least $571,339.17 as of July 24th, 2023. Ms. Aebersold owns 43,983 shares of BioLife Solutions stock worth more than $571,339 as of October 12th. This net worth evaluation does not reflect any other assets that Ms. Aebersold may own. Learn More about Sarah Aebersold's net worth.Aug 9, 2023 · What happened. Shares of BioLife Solutions ( BLFS 3.76%) were down by more than 27% as of 1:15 p.m. on Wednesday after the healthcare company posted its second-quarter earnings report. The stock ...

BioLife Solutions, Inc. (BLFS) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the ...The estimated net worth of Andrew G. Hinson is at least $207,858.00 as of June 15th, 2021. Mr. Hinson owns 17,675 shares of BioLife Solutions stock worth more than $207,858 as of November 3rd. This net worth approximation does not reflect any other investments that Mr. Hinson may own. Learn More about Andrew G. Hinson's net worth.The current stock price of is . Chart and price action Where to buy Biolife Solutions shares? Does not pay dividends in 2023. Prediction and analyst recommendations.Track Biolife Solutions Inc (BLFS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsInstagram:https://instagram. vision insurance washingtoniwm etf pricewhich dental insurance is goodbest checking accounts in michigan Discover historical prices for BLFS stock on Yahoo Finance. View daily, weekly or monthly format back to when BioLife Solutions, Inc. stock was issued. tastytrade futures commissiondental insurance for family of 4 On December 15, 2022, BioLife Solutions, Inc. (NASDAQ:BLFS) stock closed at $18.77 per share. One-month return of BioLife Solutions, Inc. (NASDAQ:BLFS) was -11.46%, and its shares lost 48.63% of ...5 Wall Street analysts have issued 1 year target prices for BioLife Solutions' stock. Their BLFS share price targets range from $22.00 to $28.00. On average, they expect the company's stock price to reach $24.60 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View analysts price targets for BLFS or ... portfolio trackers First, BioLife Solutions, Inc. stock is trading at 1.95x book value of equity, which may or may not represent a value proposition. However, it should also be noted the breakdown of its book value ...BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.